Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Ching-Yuan Kuo, MD, Po-Nan Wang, MD, Wen Li Hwang, MD, Cheng-Hwai Tzeng, MD, Li-Yuan Bai, MD, Jih-Luh Tang, MD PhD, Ming-Chih Chang, MD, Sheng-Fung Lin, MD, Tsai-Yun Chen, MD, Yeu-Chin Chen, MD, Tran-Der Tan, MD, Chih-Yi Hseih, MD, Chinjune Lin, MD, Miljkovic Darko, MD, Chang Cheng-Shyong, MD

Blood (2015) 126 (23): 1593.

https://doi.org/10.1182/blood.V126.23.1593.1593

Published: 2015

Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD

Blood (2014) 124 (21): 4544.

https://doi.org/10.1182/blood.V124.21.4544.4544

Published: 2014

Journal Articles

Hepatitis C Infection Is Associated with Hepatic Toxicity but Does Not Compromise the Survival of Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab-Based Chemotherapy

Li-Yuan Bai, MD, Tzu-Ting Chen, MD, Chang-Fang Chiu, Tse-Yen Yang, Su-Peng Yeh, MD, Yu-Min Liao, MD

Blood (2014) 124 (21): 5382.

https://doi.org/10.1182/blood.V124.21.5382.5382

Published: 2014

Journal Articles

OSU-A9, An Indole-3-Carbinol Derivative, Induces Cytotoxicity In Acute Myeloid Leukemia Through Reactive Oxygen Species-Mediated Apoptosis

Li-Yuan Bai, MD, PhD, Jing-Ru Weng, Chia-Yung Wu, Chang-Fang Chiu, Su-Peng Yeh, MD, Yu-Min Liao, MD

Blood (2013) 122 (21): 2531.

https://doi.org/10.1182/blood.V122.21.2531.2531

Published: 2013

Journal Articles

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Li-Yuan Bai, MD, Yihui Ma, Samuel K Kulp, Shu-Huei Wang, PhD, Chang-Fang Chiu, MD, DMS, Frank Frissora, Xiaokui Mo, David Jarjoura, John C. Byrd, Ching-Shih Chen, Natarajan Muthusamy, DVM., PhD

Blood (2009) 114 (22): 3778.

https://doi.org/10.1182/blood.V114.22.3778.3778

Published: 2009

NARROW

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Hepatitis C Infection Is Associated with Hepatic Toxicity but Does Not Compromise the Survival of Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab-Based Chemotherapy

OSU-A9, An Indole-3-Carbinol Derivative, Induces Cytotoxicity In Acute Myeloid Leukemia Through Reactive Oxygen Species-Mediated Apoptosis

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Email alerts

ASH Publications

American Society of Hematology

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Hepatitis C Infection Is Associated with Hepatic Toxicity but Does Not Compromise the Survival of Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab-Based Chemotherapy

OSU-A9, An Indole-3-Carbinol Derivative, Induces Cytotoxicity In Acute Myeloid Leukemia Through Reactive Oxygen Species-Mediated Apoptosis

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only